105 related articles for article (PubMed ID: 20829243)
1. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
Bojar M; Zajac M; Meluzínová E; Houžvičková E; Libertinová J; Lišková P; Mat'oška V; Nyč O; Mináriková M
Mult Scler; 2010 Dec; 16(12):1529-30; author reply 1531-2. PubMed ID: 20829243
[No Abstract] [Full Text] [Related]
2. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS
Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832
[TBL] [Abstract][Full Text] [Related]
3. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
Gneiss C; Koudouovoh-Tripp PM; Ropele S; Gotwald T; Ehling R; Lutterotti A; Aichner F; Ladurner G; Eggers C; Schautzer F; Künz B; Millonig A; Aspeck E; Reindl M; Berger T; Fazekas F; Deisenhammer F
Mult Scler; 2009 Dec; 15(12):1481-8. PubMed ID: 19965519
[TBL] [Abstract][Full Text] [Related]
4. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis.
van der Voort LF; Gilli F; Bertolotto A; Knol DL; Uitdehaag BM; Polman CH; Killestein J
Arch Neurol; 2010 Apr; 67(4):402-7. PubMed ID: 20142519
[TBL] [Abstract][Full Text] [Related]
5. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
Farrell RA; Giovannoni G
Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
[TBL] [Abstract][Full Text] [Related]
6. Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis.
Foley P; Reilly P; Coulson A; O'Riordan JI
J R Coll Physicians Edinb; 2010 Jun; 40(2):105-10. PubMed ID: 21125049
[TBL] [Abstract][Full Text] [Related]
7. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
[TBL] [Abstract][Full Text] [Related]
8. Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox.
Sørensen PS
Mult Scler; 2012 Feb; 18(2):131-2. PubMed ID: 22312007
[No Abstract] [Full Text] [Related]
9. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
McKay F; Schibeci S; Heard R; Stewart G; Booth D
J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
[TBL] [Abstract][Full Text] [Related]
10. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
11. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
Malucchi S; Capobianco M; Gilli F; Marnetto F; Caldano M; Sala A; Bertolotto A
Neurol Sci; 2005 Dec; 26 Suppl 4():S213-4. PubMed ID: 16388361
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response.
Hesse D; Krakauer M; Lund H; Søndergaard HB; Langkilde A; Ryder LP; Sorensen PS; Sellebjerg F
Neurology; 2010 May; 74(18):1455-62. PubMed ID: 20439848
[TBL] [Abstract][Full Text] [Related]
13. [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
Sørensen S; Koch-Henriksen NJ; Pedersen CR; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E;
Ugeskr Laeger; 2004 Oct; 166(41):3606-9. PubMed ID: 15515467
[No Abstract] [Full Text] [Related]
14. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients.
Gibbs E; Oger J
J Neuroimmunol; 2007 Oct; 190(1-2):146-50. PubMed ID: 17825927
[TBL] [Abstract][Full Text] [Related]
15. Can we get rid of neutralizing antibodies against interferon-β?
Buttmann M; Toyka KV
Eur J Neurol; 2009 Jan; 16(1):7-9. PubMed ID: 19087143
[No Abstract] [Full Text] [Related]
16. [Pragmatic approach to treatments in multiple sclerosis].
Vermersch P
Rev Neurol (Paris); 2009 Apr; 165 Spec No 2():F125-31. PubMed ID: 19593885
[No Abstract] [Full Text] [Related]
17. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
Boz C; Oger J; Gibbs E; Grossberg SE;
Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
[TBL] [Abstract][Full Text] [Related]
18. Landmark papers in multiple sclerosis.
Cross AH
Neurology; 2001 Dec; 57(12 Suppl 5):S1-2. PubMed ID: 11902588
[No Abstract] [Full Text] [Related]
19. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.
Bosca I; Villar LM; Coret F; Magraner MJ; Simó-Castelló M; Alvarez-Cermeño JC; Casanova B
Mult Scler; 2010 Jul; 16(7):810-5. PubMed ID: 20538705
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis.
Deisenhammer F; Giovannoni G
Mult Scler; 2004 Dec; 10(6):713-4; author reply 715. PubMed ID: 15584500
[No Abstract] [Full Text] [Related]
[Next] [New Search]